DOCSLIB.ORG

Update of the Guideline on Chronic Pruritus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Update of the Guideline on Chronic Pruritus Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum Subcommittee Members: Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Erwin Tschachler, Wien (Austria) Prof. Dr. Torello Lotti, Florence (Italy) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Laurent Misery, Brest (France) Dr. Markus Streit, Aarau (Switzerland) Prof. Dr. Thomas Mettang, Wiesbaden (Germany) Prof. Dr. Jacek Szepietowski, Wroclaw (Poland) Prof. Dr. Joanna Wallengren, Lund (Sweden) Dr. Peter Maisel, Münster (Germany) Prof. Dr. Uwe Gieler, Gießen (Germany) Prof. Dr. Malcolm Greaves (Singapore) Prof. Dr. Ulf Darsow, Munich (Germany) Prof. Dr. Julien Lambert, Antwerp (Belgium) Members of EDF Guideline Committee: Prof. Dr. Werner Aberer, Graz (Austria) Prof. Dr. Dieter Metze, Münster (Germany) Prof. Dr. Martine Bagot, Paris (France) Dr. Kai Munte, Rotterdam (Netherlands) Prof. Dr. Nicole Basset-Seguin, Paris (France) Prof. Dr. Gilian Murphy, Dublin (Ireland) Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany) Prof. Dr. Martino Neumann, Rotterdam (Netherlands) Prof. Dr. Lasse Braathen, Bern (Switzerland) Prof. Dr. Tony Ormerod, Aberdeen (UK) Prof. Dr. Sergio Chimenti, Rome (Italy) Prof. Dr. Mauro Picardo, Rome (Italy) Prof. Dr. Alexander Enk, Heidelberg (Germany) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Claudio Feliciani, Rome (Italy) Prof. Dr. Annamari Ranki, Helsinki (Finland) Prof. Dr. Claus Garbe, Tübingen (Germany) Prof. Dr. Berthold Rzany, Berlin (Germany) Prof. Dr. Harald Gollnick, Magdeburg (Germany) Prof. Dr. Rudolf Stadler, Minden (Germany) Prof. Dr. Gerd Gross, Rostock (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia) Prof. Dr. Eggert Stockfleth, Berlin (Germany) Prof. Dr. Michael Hertl, Marburg (Germany) Prof. Dr. Alain Taieb, Bordeaux (France) Prof. Dr. Dimitrios Ioannidis, Thessaloniki (Greece) Prof. Dr. George-Sorin Tiplica, Bucharest (Romania) Prof. Dr. Gregor Jemec, Roskilde (Denmark) Prof. Dr. Nikolai Tsankov, Sofia (Bulgaria) Prof. Dr. Lajos Kemény, Szeged (Hungary) Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Dr. Gudula Kirtschig (Germany) Prof. Dr. Sean Whittaker, London (UK) Prof. Dr. Robert Knobler, Wien (Austria) Prof. Dr. Fenella Wojnarowska, Oxford (UK) Prof. Dr. Annegret Kuhn, Münster (Germany) Prof. Dr. Christos Zouboulis, Dessau (Germany) Prof. Dr. Marcus Maurer, Berlin (Germany) Prof. Dr. Torsten Zuberbier, Berlin (Germany) Chairman of EDF Guideline Committee: PD Dr. Alexander Nast, Berlin (Germany) Expiry date: 01/2017 EDF Guidelines Secretariat to PD Dr. Nast: Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charité.de CONFLICT OF INTEREST STATEMENTS Conflicts of interests_p.1 Remark: no entry means “none” The Work Under Consideration for Publication Misery, Weisshaar, Lotti, Darsow, Laurent Elke Torello Ulf 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership Almirall, President World Novartis Health Academy Publishing House, Zurich, CH; Editor, Dermatologic Therapy; Executive, Vitiligo Research Foundation, USA 2 Consultancy Pierre Fabre EV Laser, Italy; GLG, USA CLINUVEL, Australia; Applied Biology, Inc, Irvine, CA, USA¸EVERETT LABORATOIRES Inc. USA; BIOSKIN EVOLUTION ©® 3 Employment University of Rome “G.Marconi”, 1 Rome, Italy 4 Expert testimony Advance Medical, Spain 5 Grants/grants BASF, Uriage Stiefel pending Laboratoriums, Förderverein Juckreizfor- schung e.V., Fresenius 6 Payment for Astellas, DGUV, BGAG lectures including Novartis Dresden, service on BGMS, BGFE, speakers bureaus Philipps-Univ. Marburg, Neurodermitis- Akademie Hessen, Thüringen, SAMA, Basilea GmbH, Stiefel Labs. GmbH, Intendis GmbH, Essex Pharma GmbH, Novartis GmbH, Sebapharma GmbH 7 Payment for Pierre Fabre Fresenius manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of educational presentations 11 Stock/stock options 12 Travel/accommodat MCAS, AMEC, ions/meeting COSMODERM, expenses unrelated CUTICON, MIB to activities listed** ESCAD, PANARAB 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially 2 influencing, what you wrote in the submitted work? 3 Conflicts of interests_p.2 Remark: no entry means “none” The Work Under Consideration for Publication Ring, Johannes Wallengren, Tschachler, Streit, Joanna Erwin Markus 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership Novartis, Pfizer, Merck 2 Consultancy Chanel S.A. 3 Employment University of Munich 4 Expert testimony 5 Grants/grants ALK Abelló, Chanel S. A. Centocor pending Allergopharma, Almirall Hermal, Astellas, Bencard, Bogen-Idec, Galderma, Glaxo Smith- Kline, Leo, MSD, Novartis, Phadia, PLS Design, Stallergenes 6 Payment for Convatec, lectures including Coloplast, service on Johnson & speakers bureaus Johnsons, Essex 4 7 Payment for manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of educational presentations 11 Stock/stock options 12 Travel/accommodat ions/meeting expenses unrelated to activities listed** 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? 5 Conflicts of interests_3 Remark: no entry means “none” The Work Under Consideration for Publication Maisel, Lambert, Greaves, Mettang, Peter Julien Malcolm Thomas 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership 2 Consultancy MEDA, FMC Germany PFIZER, MSD, ABBVIE, JANSEN- CILAG, LEO PHARMA 3 Employment 4 Expert testimony 5 Grants/grants pending 6 Payment for GSK, MEDA, FMC Germany lectures including PFIZER, MSD, Roche service on ABBVIE, speakers bureaus JANSEN- CILAG, LEO PHARMA 7 Payment for FMC Germany manuscript preparation 8 Patents (planned, pending or issued) 9 Royalties 10 Payment for development of 6 educational presentations 11 Stock/stock options 12 Travel/accommodat ions/meeting expenses unrelated to activities listed** 13 Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line. Other relationships 1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? 7 Conflicts of interests_4 Remark: no entry means “none” The Work Under Consideration for Publication Szepietowski, Gieler, Ständer, Jacek Uwe Sonja 1 Grant 2 Consulting fee or honorarium 3 Support for travel to meetings for the study or other purposes 4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like 5 Payment for writing or reviewing the manuscript 6 Provision of writing assistance, medicines, equipment, or administrative support 7 Other * This means money that your institution received for your efforts on this study. Relevant financial activities outside the submitted work 1 Board membership 2 Consultancy Abbott, Almirall, Allmiral Basilea, Bayer- Creabilis, Intendis, Daiichi Sankyo Galderma, Kneipp, Merz Glaxo-Smith Nerre Kline, Merz
Recommended publications
  • Rare Diseases: GI/Metabolic

    Rare Diseases: GI/Metabolic

    Rare Diseases: GI / Metabolic Ciara Kennedy, PhD, MBA – Head of Cholestatic Liver Disease David Piccoli, MD – Chief of Gastroenterology, Hepatology & Nutrition, Children’s Hospital Of Philadelphia Our purpose We enable people with life-altering conditions to lead better lives. The “SAFE HARBOR” Statement Under the Private Securities Litigation Reform Act of 1995 Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements can be identified by words such as “aspiration”, “will”, “expect”, “forecast”, “aspiration”, “potential”, “estimates”, “may”, “anticipate”, “target”, “project” or similar expressions suitable for identifying information that refers to future events. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: . Shire’s products may not be a commercial success; . revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014; . the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations; . Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time.
  • Itch in Ethnic Populations

    Itch in Ethnic Populations

    Acta Derm Venereol 2010; 90: 227–234 REVIEW ARTICLE Itch in Ethnic Populations Hong Liang TEY1 and Gil YOSIPOVITCH2 1National Skin Centre, 1, Mandalay Road, Singapore, Singapore, and 2Department of Dermatology, Neurobiology & Anatomy, and Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA Racial and ethnic differences in the prevalence and clini- DIFFERENCES IN SKIN BIOLOGY AND ITCH cal characteristics of itch have rarely been studied. The aim of this review is to highlight possible associations Few studies have examined the differences between between ethnicity and different forms of chronic itch. We skin types in relation to ethnicity and neurobiology of provide a current review of the prevalence of different the skin. Differences between ethnic skin types and types of itch in ethnic populations. Genetic variation may skin properties may explain racial disparities seen in significantly affect receptors for itch as well as response pruritic dermatologic disorders. to anti-pruritic therapies. Primary cutaneous amyloido- sis, a type of pruritic dermatosis, is particularly common Epidermal structure and function in Asians and rare in Caucasians and African Ameri- cans, and this may relate to a genetic polymorphism in A recent study has shown that the skin surface and the Interleukin-31 receptor. Pruritus secondary to the melanocyte cytosol of darkly pigmented skin is more use of chloroquine for malaria is a common problem for acidic compared with those of type I–III skin (1). Serine African patients, but is not commonly reported in other protease enzymes, which have significant roles as pruri- ethnic groups. In patients with primary biliary cirrho- togens in atopic eczema and other chronic skin diseases, sis, pruritus is more common and more severe in African have been shown to be significantly reduced in black Americans and Hispanics compared with Caucasians.
  • Review Article Pruritus in Systemic Diseases: a Review of Etiological Factors and New Treatment Modalities

    Review Article Pruritus in Systemic Diseases: a Review of Etiological Factors and New Treatment Modalities

    Hindawi Publishing Corporation e Scientific World Journal Volume 2015, Article ID 803752, 8 pages http://dx.doi.org/10.1155/2015/803752 Review Article Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities Nagihan Tarikci, Emek Kocatürk, Fule Güngör, IlteriG OLuz Topal, Pelin Ülkümen Can, and Ralfi Singer Department of Dermatology, Okmeydanı Training and Research Hospital, 34384 Istanbul, Turkey Correspondence should be addressed to Emek Kocaturk;¨ [email protected] Received 20 February 2015; Revised 11 June 2015; Accepted 16 June 2015 Academic Editor: Uwe Wollina Copyright © 2015 Nagihan Tarikci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pruritus is the most frequently described symptom in dermatology and can significantly impair the patient’s quality of life. In 10–50% of adults with persistent pruritus, it can be an important dermatologic clue for the presence of a significant underlying systemic disease such as renal insufficiency, cholestasis, hematologic disorder, or malignancy (Etter and Myers, 2002; Zirwas and Seraly, 2001). This review describes the presence of pruritus in different systemic diseases. It is quite important to discover the cause of pruritus for providing relief for the patients experiencing substantial morbidity caused by this condition. 1. Pruritus Endocrinal Disorders. Thyroid diseases, diabetes mellitus. Pruritus is a topic that has caused a great deal of controversy Paraneoplastic Diseases. Lymphomas and solid organ tumors. because it is difficult to characterize and define. Various indirect definitions proposed include a sensation which provokes the desire to scratch or an uneasy sensation of 2.
  • Dermatologia 2021;96(4):397---407

    Dermatologia 2021;96(4):397---407

    Anais Brasileiros de Dermatologia 2021;96(4):397---407 Anais Brasileiros de Dermatologia www.anaisdedermatologia.org.br CONTINUING MEDICAL EDUCATION Phototherapyଝ,ଝଝ ∗ Norami de Moura Barros , Lissiê Lunardi Sbroglio , Maria de Oliveira Buffara , Jessica Lana Conceic¸ão e Silva Baka , Allen de Souza Pessoa , Luna Azulay-Abulafia Department of Dermatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil Received 3 December 2019; accepted 2 March 2021 Available online 2 April 2021 Abstract Of all the therapeutic options available in Dermatology, few of them have the his- KEYWORDS tory, effectiveness, and safety of phototherapy. Heliotherapy, NB-UVB, PUVA, and UVA1 are Phototherapy; currently the most common types of phototherapy used. Although psoriasis is the most frequent PUVA therapy; indication, it is used for atopic dermatitis, vitiligo, cutaneous T-cell lymphoma, and cutaneous Ultraviolet therapy sclerosis, among others. Before indicating phototherapy, a complete patient assessment should be performed. Possible contraindications should be actively searched for and it is essential to assess whether the patient can come to the treatment center at least twice a week. One of the main method limitations is the difficulty that patients have to attend the sessions. This therapy usually occurs in association with other treatments: topical or systemic medications. Maintaining the regular monitoring of the patient is essential to identify and treat possible adverse effects. Phototherapy is recognized for its benefits and should be considered whenever possible. © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana,˜ S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
  • Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013

    Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013

    Acta Derm Venereol 2014; 94: 123 LETTER TO THE EDITOR Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013 Frank Brennan1 and Dedee F. Murrell2* 1Palliative Medicine, Calvary Hospital, 91 Rocky Point Road, and 2Department of Dermatology, St George Hospital, University of New South Wales, Gray St, Kogarah, Sydney, NSW 2217 Australia. *E-mail: [email protected] Accepted Aug 28, 2013; Epub ahead of print Oct 24, 2013 Sir, on the mechanisms and management of opioid-induced The inaugural Australian symposium on pruritus was itch. Frank Brennan spoke on uraemic pruritus, Paul Gray, convened at St George Hospital, Sydney on August 10, a Pain Specialist with a particular interest in burns spoke 2013. The co-conveners were Professor Dedee Murrell, on the phenomenon of post-burns pruritus and Craig Le- Executive Vice President of the International Society of wis, Medical Oncologist surveyed the symptom of itch Dermatology (ISD) and Dr Frank Brennan, Palliative and its management in cancer medicine. Medicine Physician. The impetus behind the symposium A feature of the day was an interview with a patient was the recognition of two facts. Firstly, the significant in front of the symposium participants. The patient developments in the understanding of the pathophysio- presented with a challenging combination of pruritus logy of pruritus in recent years and, secondly, the paucity secondary to a life-long history of atopy and, in later of education and understanding by colleagues across years, uraemic pruritus. Connie Katelaris surveyed the multiple disciplines of those developments. Given that history and immunological results of the patient and the symptom of pruritus manifests in many diseases the made clinical recommendations.
  • European Guideline Chronic Pruritus Final Version

    European Guideline Chronic Pruritus Final Version

    EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar
  • Module Test № 1 on Dermatology

    Module Test № 1 on Dermatology

    THE MINISTRY OF HEALTHCARE OF THE RUSSIAN FEDERATION FEDERAL STATE BUDGETARY EDUCATIONAL INSTITUTION OF HIGHER PROFESSIONAL EDUCATION PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY DEPARTMENT OF DERMATOVENEROLOGY Gaydina T.A., Dvornikov A.S., Skripkina P.A., Nazhmutdinova D.K., Heydar S.A., Arutunyan G.B., Pashinyan A.G. MODULE TEST №1 ON DERMATOLOGY FOR STUDENTS OF INSTITUTES OF HIGHER MEDICAL EDUCATION ON SPECIALTY THERAPEUTIC FACULTY DEPARTMENT OF DERMATOVENEROLOGY Moscow 2016 ISBN УДК ББК A21 Module test №1 on Dermatology for students of institutes of high medical education on specialty «Therapeutic faculty» department of dermatovenerology: manual for students for self-training//FSBEI HPE “Pirogov RNRMU” of the ministry of healthcare of the russian federation, M.: (publisher) 2016, 144 p. The manual is a part of teaching-methods on Dermatovenerology. It contains tests on Dermatology on the topics of practical sessions requiring single or multiple choice anser. The manual can be used to develop skills of students during practical sessions. It also can be used in the electronic version at testing for knowledge. The manual is compiled according to FSES on specialty “therapeutic faculty”, working programs on dermatovenerology. The manual is intended for foreign students of 3-4 courses on specialty “therapeutic faculty” and physicians for professional retraining. Authors: Gaydina T.A. – candidate of medical science, assistant of dermatovenerology department of therapeutic faculty Pirogov RNRMU Dvornikov A.S. – M.D., professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Skripkina P.A. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Nazhmutdinova D.K. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Heydar S.A.
  • Pruritus: Scratching the Surface

    Pruritus: Scratching the Surface

    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
  • Abstracts from the 9Th World Congress on Itch October 15–17, 2017

    Abstracts from the 9Th World Congress on Itch October 15–17, 2017

    ISSN 0001-5555 ActaDV Volume 97 2017 SEPTEMBER, No. 8 ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Abstracts from the 9th World Congress on Itch October 15–17, 2017 Official Journal of - European Society for Dermatology and Wroclaw, Poland Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv Abstracts from the 9th World Congress on Itch DV cta A enereologica V Organizing Committee Scientific Committee ermato- Congress President: Jacek C Szepietowski (Wroclaw, Poland) Jeffrey D. Bernhard (Massachusetts, USA) D Congress Secretary General: Adam Reich (Rzeszów, Poland) Earl Carstens (Davis, USA) Congress Secretary: Edyta Lelonek (Wroclaw, Poland) Toshiya Ebata (Tokyo, Japan) cta Alan Fleischer (Lexington, USA) A IFSI President: Earl Carstens (Davis, USA) IFSI Vice President: Elke Weisshaar (Heidelberg, Germany) Ichiro Katayama (Osaka, Japan) Ethan Lerner (Boston, USA) Staff members of the Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland Thomas Mettang (Wiesbaden, Germany) Martin Schmelz (Mannheim, Germany) Sonja Ständer (Münster, Germany) DV Jacek C. Szepietowski (Wroclaw, Poland) cta Kenji Takamori (Tokyo, Japan) A Elke Weisshaar (Heidelberg, Germany) Gil Yosipovitch (Miami, USA) Contents of this Abstract book Program 1000 Abstracts: Lecture Abstracts 1008 Poster Abstracts 1035 Author Index 1059 dvances in dermatology and venereology A www.medicaljournals.se/acta doi: 10.2340/00015555-2773 Journal Compilation © 2017 Acta Dermato-Venereologica. Acta Derm Venereol 2017; 97: 999–1060 1000 9th World Congress of Itch Sunday, October 15, 2017 Abstract # 1:30-3:30 PM IFSI Board meeting DV 5:00-5:20 PM OPENING CEREMONY 5:00-5:10 PM Opening remarks cta Jacek C.

  • World Journal of Dermatology

    World Journal of W J D Dermatology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Dermatol 2015 May 2; 4(2): 108-113 Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx ISSN 2218-6190 (online) DOI: 10.5314/wjd.v4.i2.108 © 2015 Baishideng Publishing Group Inc. All rights reserved.V MINIREVIEWS New innovation of moisturizers containing non-steroidal anti-inflammatory agents for atopic dermatitis Montree Udompataikul Montree Udompataikul, Skin Center, Srinakharinwirot experience. These moisturizers might be considered University, Bangkok 10110, Thailand as an alternative treatment in acute flare of mild to Author contributions: Udompataikul M contributed to this moderate atopic dermatitis. work. Conflict-of-interest:None. Key words: Non-steroidal anti-inflammatory agents; Open-Access: This article is an open-access article which was Moisturizer; Atopic dermatitis selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, © The Author(s) 2015. Published by Baishideng Publishing which permits others to distribute, remix, adapt, build upon this Group Inc. All rights reserved. work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and Core tip: The skin care management particular moisturizers the use is non-commercial. See: http://creativecommons.org/ play an important role in atopic dermatitis. The side effects licenses/by-nc/4.0/ of corticosteroids are limited in their use in this disease. Correspondence to: Montree Udompataikul, MD, Associate Take together, a new moisturizer containing various anti- Prefessor, Skin Center, Srinakharinwirot University, Sukhumvit 23, Wattana, Bangkok 10110, Thailand.
  • Pruritus Ani (Itchy Bottom)

    Pruritus Ani (Itchy Bottom)

    PRURITUS ANI (ITCHY BOTTOM) What is pruritus ani? Pruritus ani means a chronic (persistent) itchy feeling around the anus. The main symptom is an urge to scratch your anus which is difficult to resist. The urge to scratch may occur at any time. However, it tends to be more common after you have been to the toilet to pass faeces, and at night (particularly just before falling asleep). The itch may be made worse by heat, wool, moisture, leaking, soiling, stress, and anxiety. About 1 in 20 people develop pruritus ani at some stage. It is common in both adults and children. What causes pruritus ani? Pruritus ani is a symptom, not a final diagnosis. Various conditions may cause pruritus ani. However, in many cases the cause is not clear. This is called ‘idiopathic pruritus ani’, which means ‘itchy anus of unknown cause’. Known causes of pruritus ani There are various causes which include the following: Inflamed anal skin is a common cause (a localised dermatitis). The inflammation is usually due to the skin ‘reacting’ to small amounts of faeces (sometimes called stools or motions) left on the skin, and/or to sweat and moisture around the anus. Young children who may not wipe themselves properly, adults with sweaty jobs, and adults with a lot of hair round the anus may be especially prone to this. Thrush and fungal infections. These germs like it best in moist, warm, airless areas, such as around the anus. Thrush is more common in people with diabetes. Other infections such as scabies, herpes, anal warts and some other sexually transmitted diseases can cause itch around the anus.
  • Clinical Spectrum of Ageing Versus Non-Ageing Geriatric Dermatoses -A Case-Controlled Study in Tertiary Care Centre, Tamil Nadu, South India

    Clinical Spectrum of Ageing Versus Non-Ageing Geriatric Dermatoses -A Case-Controlled Study in Tertiary Care Centre, Tamil Nadu, South India

    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(2):151–159 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Clinical spectrum of ageing versus non-ageing geriatric dermatoses -A case-controlled study in tertiary care centre, Tamil Nadu, South India C Abhirami1, P K Kaviarasan1,*, B Poorana1, K Kannambal1, P V S Prasad1, N Chidambaram2 1Dept. of Dermatology Venereology & Leprosy, Rajah Muthiah Medical College and Hospital, Annamalai University, Chidambaram, Tamil Nadu, India 2Dept. of Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, Chidambaram, Tamil Nadu, India ARTICLEINFO ABSTRACT Article history: Introduction: Ageing process is a complex phenomenon which affects all organs in the body as well as Received 17-05-2020 skin. Geriatric dermatoses can be regarded as a cutaneous marker of underlying systemic disorders and Accepted 29-05-2020 internal malignancies. This was study aimed to analyse various clinical ageing patterns among elderly aged Available online 25-06-2020 above 60 years. Objectives: To determine the prevalence of clinical patterns of ageing and non-ageing dermatoses among elderly compare with non-dermatology patients. Keywords: Materials and Methods: An observational study, conducted on 300 patients aged 60 years and above were Ageing analysed for geriatric dermatoses. Of them 211 patients were subjects attended dermatology OPD (group Dermatoses A) and 89 patients were controls (Group B) from other were selected from specialties.. Detailed history, Geriatric through examination and appropriate investigations were done after obtaining informed consent. Pruritus Ageing Results: Out of 300 patients, males were (192, 64%) and females (108, 36%), the male female ratio of Pruritus 1.77:1.